coronavirus patients. "These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised Covid-19 patients," the WHO said in a statement.
Artesunate is already used for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn's Disease and rheumatoid arthritis.
Meanwhile, the highly-transmissible Delta variant of Covid-19 has now been reported in 135 countries, as per the WHO, which said the cumulative number of coronavirus cases reported globally could exceed 200 million by next week.